Physicians' Academy for Cardiovascular Education

Lipids

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD

Changing the paradigm on LDL-c-lowering in high CV risk patients

10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Combination therapy to achieve lower LDL-c goals is the way forward

3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Addressing lipid risk: a system-wide approach to implementation

5' education - Feb. 27, 2020 - Jorge Plutzky, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Patient-reported cognition at the end of a PCSK9 antibody trial

5' education - Nov. 17, 2019 - Baris Gencer, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

The mechanism of action of bempedoic acid

Feb. 2, 2020

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?

10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

E-learning Redefining intensive LDL-c management in high CV risk patients – The case for combination therapy

Accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?

Understanding the increased CV risk of high Lp(a) levels

10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD
Prof. Kronenberg talks about the epidemiology and genetic basis of Lp(a) levels and explains why and when Lp(a) should be measured.

Prof. Kronenberg talks about the epidemiology and genetic basis of Lp(a) levels and explains why and when Lp(a) should be measured.

ESC debate | Do patients benefit from omega-3 fatty acids?

News - Sep. 7, 2021
Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

Changing the paradigm on LDL-c-lowering in high CV risk patients

10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD
Prof. Ray explains why monotherapy is not sufficient, and thus combination therapy is needed to reach LDL-c goals in patients with high CV risk.

Prof. Ray explains why monotherapy is not sufficient, and thus combination therapy is needed to reach LDL-c goals in patients with high CV risk.

Use of lipid lowering therapy in patients at high and very high CV risk in Europe

News - Aug. 31, 2021

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.

Treament intertia for lipid-lowering therapy in patients with FH and CVD

Literature - Aug. 9, 2021 - Langer A et al. - J Am Heart Assoc. 2021

Physician reminders for recommended LLT led to an increase in the proportion of patients with FH and/or CVD achieving LDL-c treatment goals. However, treatment inertia exists in patients with FH, including those with established CVD.

Two-thirds of ASCVD patients in the US do not reach LDL-c <70 mg/dL after 2 years on LLT

Literature - June 30, 2021 - Cannon CP et al. - JAMA Cardiol. 2021

This prospective registry study in the US showed that only 17.1% of patients with ASCVD on LLT had their therapy intensified over the next 2 years. Only 31.7% of patients achieved LDL-c levels <70mg/dL at 2 years.

Sustained CV benefits of statin treatment after discontinuation

Literature - May 12, 2021 - Bosch J et al. - Eur Heart J. 2021

CV benefits of rosuvastatin, compared with placebo, are sustained or enhanced even after stopping therapy in individuals without CVD but at intermediate risk for CV events.

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD
Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

Prof. Stephen Nicholls discusses the results of a study that investigated the lipid-lowering effects of triple therapy with bempedoic acid, ezetimibe and statin as a new potential strategy for treating hypercholesterolemia.

ApoB and non-HDL-c are better markers of residual risk than LDL-c in statin-treated patients

Literature - Apr. 7, 2021 - Johannesen CDL et al. - J Am Coll Cardiol. 2021

Elevated levels of apoB and non-HDL-c better reflect residual risk for all-cause mortality and MI than LDL-c levels in patients treated with statins.

Elevated Lp(a) associated with large artery atherosclerosis stroke and risk of recurrent stroke

Literature - Mar. 23, 2021 - Arnold M et al. - Eur Heart J. 2021

The prospective BIOSIGNAL cohort study showed that elevated Lp(a) was independently associated with LAA stroke etiology and risk of recurrent AIS or TIA in patients <60 years.

Elevated Lp(a) associated with CAD in individuals without a family history of CVD

Literature - Mar. 8, 2021 - Finneran P et al. - J Am Heart Assoc. 2021

This study investigated the risk of incident CAD in participants from the UK Biobank with and without a family history of CVD in a sibling or parent.